Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 6/20 | 1.00 |
| ▸ | CDC25B | P30305 | 6/20 | 1.00 |
| ▸ | ALPG | P10696 | 12/20 | 0.90 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | ALPL | P05186 | 4/20 | 0.69 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143469 | 0.90 | ALPG (1.00) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL4137109 | 0.90 | ALPG (1.00) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL4148048 | 0.88 | ALPG (1.00) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL6192068 | 0.88 | MAPT (0.91) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL6839263 | 0.85 | MAPT (0.85) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL6211001 | 0.83 | MAPT (0.82) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL5338687 | 0.82 | MAPT (0.76) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL6408692 | 0.80 | MAPT (0.79) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL6211327 | 0.80 | CDC25A (0.83) | CDC25ACDC25BALPGMAPTLMNA | |
| SCHEMBL6274937 | 0.78 | MAPT (0.77) | CDC25ACDC25BALPGMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009078587-A2 | COMPOSITION FOR PREVENTION AND TREATMENT OF CANCER CONTAINING TRIAZOLYL-THIO-ETHANONE DERIVATIVES INHIBITING ACTIVITY OF PROTEIN PHOSPHATASES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-06-25 | — | — | WO | claimed |
| US-20040171650-A1 | Novel anthelmintic and insecticidal compositions | LEE BYUNG HYUN (US) | 2004-09-02 | — | — | US | claimed |
| WO-2009078587-A2 | COMPOSITION FOR PREVENTION AND TREATMENT OF CANCER CONTAINING TRIAZOLYL-THIO-ETHANONE DERIVATIVES INHIBITING ACTIVITY OF PROTEIN PHOSPHATASES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171650-A1 | Novel anthelmintic and insecticidal compositions | ACHE, AADAC, BCHE | CDC25A 2487/4885CDC25B 2189/4885ALPG 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.